-
2
-
-
3142768949
-
Chemotherapy for malignant pleural mesothelioma: past results and recent developments
-
Tomek S., and Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 455 (2004) S103-S119
-
(2004)
Lung Cancer
, vol.455
-
-
Tomek, S.1
Manegold, C.2
-
3
-
-
33846327132
-
Lung Cancer Disease Site Group of Cancer Care Ontario's Program in evidence-based care. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline
-
Ellis P., Davies A.M., Evans W.K., Haynes A.E., and Lloyd N.S. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in evidence-based care. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 1 (2006) 591-601
-
(2006)
J Thorac Oncol
, vol.1
, pp. 591-601
-
-
Ellis, P.1
Davies, A.M.2
Evans, W.K.3
Haynes, A.E.4
Lloyd, N.S.5
-
4
-
-
46349091630
-
Current concepts in chemotherapy for malignant pleural mesothelioma
-
Sørensen J.B. Current concepts in chemotherapy for malignant pleural mesothelioma. Clin Respir J 2 (2008) 74-79
-
(2008)
Clin Respir J
, vol.2
, pp. 74-79
-
-
Sørensen, J.B.1
-
5
-
-
0036837690
-
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature and meta-analysis
-
Berghmans T., Paesmans M., Lalami Y., Louviaux I., Luce S., Mascaux C., et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature and meta-analysis. Lung Cancer 38 (2002) 111-121
-
(2002)
Lung Cancer
, vol.38
, pp. 111-121
-
-
Berghmans, T.1
Paesmans, M.2
Lalami, Y.3
Louviaux, I.4
Luce, S.5
Mascaux, C.6
-
6
-
-
0034548837
-
Phase II study of vinorelbine in patients with malignant pleural mesothelioma
-
Steele J.P.C., Shamash J., Evans M.T., Gower N.H., Tischkowitz M.D., and Rudd R.M. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18 (2000) 3912-3917
-
(2000)
J Clin Oncol
, vol.18
, pp. 3912-3917
-
-
Steele, J.P.C.1
Shamash, J.2
Evans, M.T.3
Gower, N.H.4
Tischkowitz, M.D.5
Rudd, R.M.6
-
7
-
-
46349111832
-
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
-
Sørensen J.B., Frank H., and Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 99 (2008) 44-50
-
(2008)
Br J Cancer
, vol.99
, pp. 44-50
-
-
Sørensen, J.B.1
Frank, H.2
Palshof, T.3
-
8
-
-
0041629528
-
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
-
Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
-
(2003)
J Clin Oncol
, vol.21
, pp. 2636-2644
-
-
Vogelzang, N.J.1
Rusthoven, J.J.2
Symanowski, J.3
Denham, C.4
Kaukel, E.5
Ruffie, P.6
-
9
-
-
58149083475
-
Systemic treatments for mesothelioma: standard and novel
-
Kindler H.L. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 9 (2008) 171-179
-
(2008)
Curr Treat Options Oncol
, vol.9
, pp. 171-179
-
-
Kindler, H.L.1
-
10
-
-
3042575322
-
Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent
-
Adjei A.A. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 10 (2004) 4276s-4280s
-
(2004)
Clin Cancer Res
, vol.10
-
-
Adjei, A.A.1
-
11
-
-
20644466217
-
New agents in the management of advanced mesothelioma
-
Vogelzang N.J., Porta C., and Mutti L. New agents in the management of advanced mesothelioma. Semin Oncol 32 (2005) 336-350
-
(2005)
Semin Oncol
, vol.32
, pp. 336-350
-
-
Vogelzang, N.J.1
Porta, C.2
Mutti, L.3
-
12
-
-
0037842139
-
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma
-
Scagliotti G.V., Shin D.M., Kindler H.L., Vasconcelles M.J., Keppler U., Manegold C., et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21 (2003) 1556-1561
-
(2003)
J Clin Oncol
, vol.21
, pp. 1556-1561
-
-
Scagliotti, G.V.1
Shin, D.M.2
Kindler, H.L.3
Vasconcelles, M.J.4
Keppler, U.5
Manegold, C.6
-
13
-
-
0034046032
-
An assessment of the antithymine and antipurine characteristics of MTA (LY 231514) in CCRF-CEM cells
-
Chen V.J., Bewley J.R., Smith P.G., Andis S.L., Schultz R.M., Iversen P.W., et al. An assessment of the antithymine and antipurine characteristics of MTA (LY 231514) in CCRF-CEM cells. Adv Enzyme Regul 40 (2000) 143-154
-
(2000)
Adv Enzyme Regul
, vol.40
, pp. 143-154
-
-
Chen, V.J.1
Bewley, J.R.2
Smith, P.G.3
Andis, S.L.4
Schultz, R.M.5
Iversen, P.W.6
-
14
-
-
0037446057
-
Review of a promising new agent-pemetrexed disodium
-
Paz-Ares L., Bezares S., Tabernero J.M., Castellanos D., and Cortes-Funes H. Review of a promising new agent-pemetrexed disodium. Cancer 97 8 Suppl. (2003) 2056-2063
-
(2003)
Cancer
, vol.97
, Issue.8 SUPPL
, pp. 2056-2063
-
-
Paz-Ares, L.1
Bezares, S.2
Tabernero, J.M.3
Castellanos, D.4
Cortes-Funes, H.5
-
15
-
-
0141963117
-
Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?
-
Gasparini G., Longo R., Sarmiento R., and Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. Lancet Oncol 4 (2003) 605-615
-
(2003)
Lancet Oncol
, vol.4
, pp. 605-615
-
-
Gasparini, G.1
Longo, R.2
Sarmiento, R.3
Morabito, A.4
-
16
-
-
23844462448
-
Role of COX-2 selective inhibitors for prevention and treatment of cancer
-
Amir M., and Agarwal H.K. Role of COX-2 selective inhibitors for prevention and treatment of cancer. Pharmazie 60 (2005) 563-570
-
(2005)
Pharmazie
, vol.60
, pp. 563-570
-
-
Amir, M.1
Agarwal, H.K.2
-
17
-
-
27644555091
-
Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?
-
Hull M.A. Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?. Eur J Cancer 41 (2005) 1854-1863
-
(2005)
Eur J Cancer
, vol.41
, pp. 1854-1863
-
-
Hull, M.A.1
-
18
-
-
0034026144
-
Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines
-
Hida T., Kozaki K., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6 (2000) 2006-2011
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2006-2011
-
-
Hida, T.1
Kozaki, K.2
Muramatsu, H.3
Masuda, A.4
Shimizu, S.5
Mitsudomi, T.6
-
19
-
-
0345549483
-
Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition
-
Totzke G., Schulze-Osthoff K., and Janicke R.U. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 22 (2003) 8021-8030
-
(2003)
Oncogene
, vol.22
, pp. 8021-8030
-
-
Totzke, G.1
Schulze-Osthoff, K.2
Janicke, R.U.3
-
20
-
-
0036278887
-
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma
-
Edwards J.G., Faux S.P., Plummer S.M., Abrams K.R., Walker R.A., Waller D.A., et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 8 (2002) 1857-1862
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1857-1862
-
-
Edwards, J.G.1
Faux, S.P.2
Plummer, S.M.3
Abrams, K.R.4
Walker, R.A.5
Waller, D.A.6
-
21
-
-
2442467100
-
Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma
-
Baldi A., Santini D., Vasaturo F., Santini M., Vicidomini G., Di Marino M.P., et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 59 (2004) 428-433
-
(2004)
Thorax
, vol.59
, pp. 428-433
-
-
Baldi, A.1
Santini, D.2
Vasaturo, F.3
Santini, M.4
Vicidomini, G.5
Di Marino, M.P.6
-
22
-
-
22144439371
-
Cyclooxygenase-2 predicts survival in malignant pleural mesothelioma
-
O'Kane S.L., Cawkwell L., Campbell A., and Lind M.J. Cyclooxygenase-2 predicts survival in malignant pleural mesothelioma. Eur J Cancer 41 (2005) 1645-1648
-
(2005)
Eur J Cancer
, vol.41
, pp. 1645-1648
-
-
O'Kane, S.L.1
Cawkwell, L.2
Campbell, A.3
Lind, M.J.4
-
23
-
-
1342330958
-
Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention
-
Catalano A., Graciotti L., Rinaldi, Raffaelli G., Rodilossi S., Betta P., et al. Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer 109 (2004) 322-328
-
(2004)
Int J Cancer
, vol.109
, pp. 322-328
-
-
Catalano, A.1
Graciotti, L.2
Rinaldi3
Raffaelli, G.4
Rodilossi, S.5
Betta, P.6
-
24
-
-
15044361542
-
Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer
-
Richardson C.M., Richardson D., Swinson D.E., Swain W.A., Cox G., and O'Byrne K.J. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. Lung Cancer 48 (2005) 47-57
-
(2005)
Lung Cancer
, vol.48
, pp. 47-57
-
-
Richardson, C.M.1
Richardson, D.2
Swinson, D.E.3
Swain, W.A.4
Cox, G.5
O'Byrne, K.J.6
-
25
-
-
27144467703
-
Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels
-
Shin Y.K., Park J.S., Kim H.S., Jun H.J., Kim G.E., Suh C.O., et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 65 (2005) 9501-9509
-
(2005)
Cancer Res
, vol.65
, pp. 9501-9509
-
-
Shin, Y.K.1
Park, J.S.2
Kim, H.S.3
Jun, H.J.4
Kim, G.E.5
Suh, C.O.6
-
26
-
-
38949198706
-
The proteomic analysis of cisplatin resistance in breast cancer cells
-
Smith L., Welham K.J., Watson M.B., Drew P.J., Lind M.J., and Cawkwell L. The proteomic analysis of cisplatin resistance in breast cancer cells. Oncol Res 16 (2007) 497-506
-
(2007)
Oncol Res
, vol.16
, pp. 497-506
-
-
Smith, L.1
Welham, K.J.2
Watson, M.B.3
Drew, P.J.4
Lind, M.J.5
Cawkwell, L.6
-
27
-
-
33750691670
-
Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma
-
Spugnini E.P., Cardillo I., Verdina A., Crispi S., Saviozzi S., Calogero R., et al. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res 12 (2006) 6133-6143
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6133-6143
-
-
Spugnini, E.P.1
Cardillo, I.2
Verdina, A.3
Crispi, S.4
Saviozzi, S.5
Calogero, R.6
-
28
-
-
44949244913
-
Molecular analysis of the effects of piroxicam and cisplatin on mesothelioma cells growth and viability
-
Verdina A., Cardillo I., Nebbioso A., Galati R., Menegozzo S., Altucci L., et al. Molecular analysis of the effects of piroxicam and cisplatin on mesothelioma cells growth and viability. J Transl Med 6 (2008) 27
-
(2008)
J Transl Med
, vol.6
, pp. 27
-
-
Verdina, A.1
Cardillo, I.2
Nebbioso, A.3
Galati, R.4
Menegozzo, S.5
Altucci, L.6
-
29
-
-
33745238704
-
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors
-
Grösch S., Maier T.J., Schiffmann S., and Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98 (2006) 736-747
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 736-747
-
-
Grösch, S.1
Maier, T.J.2
Schiffmann, S.3
Geisslinger, G.4
-
30
-
-
58149486385
-
NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells
-
John-Aryankalayil M., Palayoor S.T., Cerna D., Falduto M.T., Magnuson S.R., and Coleman C.N. NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Mol Cancer Ther 8 (2009) 261-273
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 261-273
-
-
John-Aryankalayil, M.1
Palayoor, S.T.2
Cerna, D.3
Falduto, M.T.4
Magnuson, S.R.5
Coleman, C.N.6
-
31
-
-
38049041523
-
Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation.
-
Peng H.L., Zhang G.S., Liu J.H., Gong F.J., and Li R.J. Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation. Ann Hematol 87 (2008) 121-129
-
(2008)
Ann Hematol
, vol.87
, pp. 121-129
-
-
Peng, H.L.1
Zhang, G.S.2
Liu, J.H.3
Gong, F.J.4
Li, R.J.5
-
32
-
-
34548682769
-
Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy
-
Banu N., Buda A., Chell S., Elder D., Moorghen M., Paraskeva C., et al. Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy. Cell Prolif 40 (2007) 768-779
-
(2007)
Cell Prolif
, vol.40
, pp. 768-779
-
-
Banu, N.1
Buda, A.2
Chell, S.3
Elder, D.4
Moorghen, M.5
Paraskeva, C.6
-
33
-
-
49049094938
-
NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein
-
Chen X.J., Xiao W., Qu X., and Zhou S.Y. NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein. Neoplasma 55 (2008) 200-204
-
(2008)
Neoplasma
, vol.55
, pp. 200-204
-
-
Chen, X.J.1
Xiao, W.2
Qu, X.3
Zhou, S.Y.4
-
34
-
-
33144485911
-
COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals
-
Han S., and Roman J. COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals. Lung Cancer 51 (2006) 283-296
-
(2006)
Lung Cancer
, vol.51
, pp. 283-296
-
-
Han, S.1
Roman, J.2
-
35
-
-
42649093479
-
Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells
-
Li S., Tong Q., Zhang W., Wang Q., Chen Z., and Wu Q. Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells. Cancer Invest 26 (2008) 333-337
-
(2008)
Cancer Invest
, vol.26
, pp. 333-337
-
-
Li, S.1
Tong, Q.2
Zhang, W.3
Wang, Q.4
Chen, Z.5
Wu, Q.6
-
36
-
-
0037652020
-
The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis
-
Minter H.A., Eveson J.W., Huntley S., Elder D.J., and Hague A. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res 9 (2003) 1885-1897
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1885-1897
-
-
Minter, H.A.1
Eveson, J.W.2
Huntley, S.3
Elder, D.J.4
Hague, A.5
|